Latest Gonorrhea Stories
The National Coalition of STD Directors (NCSD) is requesting $53.48 million in emergency funding from Congress to help prepare our public health first responders for reality of drug-resistant gonorrhea. WASHINGTON, April 23, 2013 /PRNewswire/ -- Gonorrhea has long been one of the most commonly-reported sexually transmitted diseases (STDs) in the U.S. and, unfortunately, with rising antimicrobial resistance, it has also become one of the most frightening for public health. We are now...
Lawrence LeBlond for redOrbit.com - Your Universe Online Yesterday (Feb 14) was a day of love for most people, celebrating that love by sending romantic cards, fragrant flowers and decadent chocolates to their significant others. But the day that so often ends up with lovers hitting the hay for a little after-hours, extra-curricular activity, may be more troublesome than what they had anticipated. This comes thanks to a new US Centers for Disease Control and Prevention (CDC) report...
SUNNYVALE, Calif., Jan. 15, 2013 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the U.S. Food & Drug Administration (FDA) has categorized Cepheid's Xpert(®) CT/NG test as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA). Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The test runs on Cepheid's GeneXpert(®) Systems and is...
SUNNYVALE, Calif., Dec. 27, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert(®) CT/NG. Running on Cepheid's GeneXpert(®) Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). For the first time, same-day patient consultation and treatment is possible for...
New UCSF/Kaiser Permanente study shows low risk following insertion of intrauterine devices with same-day screening The risk of developing pelvic inflammatory disease (PID) following insertion of an intrauterine device (IUD) is very low, whether or not women have been screened beforehand for gonorrhea and chlamydia, according to a joint study of nearly 60,000 women by researchers at the University of California, San Francisco (UCSF), and Kaiser Permanente Northern California Division of...
SAN DIEGO, Oct. 17, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data show continued differentiation of the company's fourth-generation macrolide/fluoroketolide, solithromycin, from currently available macrolides. The data will be presented at the IDWeek 2012(TM) conference on Oct. 17- 21 in San Diego....
CHAPEL HILL, N.C., Oct. 4, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced positive top-line data showing that solithromycin cleared infections in patients with uncomplicated urogenital gonorrhea. Patients with proven gonococcal infections were treated with a single oral dose of solithromycin. "Gonorrhea...
California's pediatricians-in-training are not adequately educated about the methods to prevent recurrent sexually transmitted infections in teenagers. That's the conclusion of a study from the Stanford University School of Medicine and Lucile Packard Children's Hospital examining pediatric residents' knowledge of laws governing treatment of their patients' sexual partners. "Unless you treat the partner, your patient gets re-infected," Neville Golden, MD, an adolescent medicine specialist...
WHITE CITY, Ore., Sept. 6, 2012 /PRNewswire/ -- BioMed Diagnostics, Inc., an innovative manufacturer of microbiology devices that facilitate and enhance infectious disease diagnosis, today reported that the unique design of its InTray(TM) GC device can help healthcare providers implement new federal guidelines for the treatment of gonorrhea, one of the most common sexually transmitted diseases (STDs.) The changes announced last month by the Centers for Disease Control and...
CHAPEL HILL, N.C., June 12, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP) today announced the dosing of the first two patients enrolled in a Phase 2 clinical trial to evaluate the efficacy, safety and tolerability of solithromycin in the treatment of uncomplicated urogenital gonococcal infections. The Phase 2 clinical trial is an open-label, single-center study of 30 patients with clinically-proven uncomplicated gonorrhea that will be treated with a single 1,200 mg oral dose of...
